Paladin Labs, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Paladin Labs, Inc.
Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.
Plus deals involving Advanz/Dimerix, Boehringer Ingelheim/Zeiss Medical Technology, Roche/Ionis, Kriya/Everads and updates from the world of technology transfer.
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
The French non-profit, whose IP is incorporated in Zolgensma, is taking its Crigler-Najjar gene therapy into a pivotal study on its own for now. It hopes to be ready for an EU filing in two years.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Allon Therapeutics, Inc.
- Ativa Pharma S.A,
- Labopharm Inc.
- ViRexx Medical Corp.
- Triton Pharma Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.